Finnish manufacturer to invest $55M+ in new facility for AAV therapies

Finnish bio­phar­ma­ceu­ti­cal con­tract man­u­fac­tur­er Biov­ian Oy is in­vest­ing €50 mil­lion ($55.3 mil­lion) to ex­pand its man­u­fac­tur­ing pres­ence in Fin­land and take on large-scale vi­ral vec­tor de­vel­op­ment.

Biov­ian said Wednes­day the new fa­cil­i­ty in Turku will be around 69,000 square feet and will house equip­ment and oth­er tech to sup­port the de­vel­op­ment and man­u­fac­tur­ing of “ad­vanced ther­a­py med­i­c­i­nal prod­ucts, in­clud­ing AAV ther­a­pies” and mi­cro­bial pro­teins.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN